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Key Points
• IUHCT of human cord
blood–derived CD341
cells into fetal NSG
mice results in systemic
multilineage engraft-
ment with human cells.
• Preconditioning with in
utero injection of an
anti-c-Kit receptor anti-
body (ACK2) results in
an improved rate of
engraftment.
Introduction
In utero hematopoietic cell transplantation (IUHCT) is a potential therapy for the treatment of numerous
genetic diseases such as hemoglobinopathies, immunodeficiencies, and inborn errors of metabolism.1 In
utero therapy offers the benefit of avoiding host myeloablation and immunosuppression and has been
shown to be successful in multiple animal models, including mice,2-5 dogs,6,7 pigs,8,9 and sheep.10-12
The timing of IUHCT exposes the transplanted human cells to the normal fetal migratory and
developmental cues that facilitate proper stem cell distribution and differentiation.11,12 Clinically, IUHCT
has been successful for fetuses with severe combined immunodeficiency (SCID),13,14 but therapeutic
uses for other diseases, including hemoglobinopathies, have seen limited success.15 Further
investigations identified multiple barriers to successful engraftment, including lack of space within the
hematopoietic niche16,17 and the maternal immune system.2,18 Among available animal models of
IUHCT, the fetal mouse remains an efficient and reproducible model to study the differentiation of stem
cells in a nonirradiated host. NSG (NOD-SCID IL2Rg-null) mice, which are developed with SCID and
IL-2Rg-null chain mutations, are a robust platform for the engraftment of human hematopoietic cells
because they have no endogenous T, B, or natural killer cells.19-22 In this study, we used IUHCT of
human CD341 cells in NSG mice to create a reproducible mouse model to study stem cell engraftment,
differentiation, and systemic repopulation after IUHCT.
Methods
Mice
NSG mice were obtained from The Jackson Laboratory. All procedures were performed according to a
University of California, San Francisco Institutional Animal Care and Use Committee–approved protocol.
Study design
Human cord blood CD341 cells were either purchased from AllCells (Alameda, CA) or purified from
cord blood collected at time of delivery from normal-term infants. CD341 cells were isolated and
transplanted into fetal mice at embryonic day 13.5 (E13.5) or E14.5 as previously described23 with or
without preconditioning with ACK2.17 Chimerism levels were checked at 4-week intervals and at harvest
using flow cytometry and immunohistochemistry.
Please see supplemental Methods for a more detailed description of the methods used.
Results and discussion
Stable, multilineage chimerism in humanized mice after in utero transplantation of
human cord blood CD341 cells
We first determined whether IUHCT in NSG mice would result in efficient engraftment and injected fetal
NSG mice at E14.5 with 25 000 to 50 000 human cord blood CD341 cells per pup using an intrahepatic
is lower than we previously reported in wild-type mice24 and likely
represents the fragility of the immunodeficient mouse model
compared with BALB/c or B6 dams. Overall, 25 of 49 (51%) mice
were found to be engrafted with human hematopoietic cells. The
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Figure 1. Stable, multilineage chimerism in humanized mice after in utero transplantation of human cord blood CD34
1
cells. (A) Experimental design for in utero
transplantation timing and measurements of blood chimerism levels. Arrows indicate time points for peripheral blood chimerism checks. (B) Representative gating strategy of
peripheral blood to detect human CD451 cells. (C) Percentage of human CD451 cells in peripheral blood over time (n 5 25, *P , .05, **P , .01 by Student t test comparing
chimerism levels each week to the initial 4-week level). (D) Representative gating strategy for lineage-specific chimerism, FoxP31 cells, and confirmation of the presence of
CD341 cells within the bone marrow. Chimeric mice demonstrated different relative proportions of granulocytes, monocytes, B cells, and T cells. (E) Compiled lineage data in
10 individual mice with evidence of CD341 cells in the bone marrow (n 5 10). CB, cord blood; SSC-A, side scatter.
injection method that we previously described utilizing 
murine hematopoietic stem cells23 (Figure 1A). A total of 57% of 
injected dams delivered viable pups; 74 of 206 transplanted pups 














































































levels of human cells in peripheral blood (chimerism) were de-
termined by flow cytometry every 4 weeks for 16 to 24 weeks
(Figure 1A-B). Peripheral blood chimerism increased over time in 23
of 25 mice from the initial analysis at the time of 4 weeks after birth to
the time of harvest (Figure 1C).
Flow cytometry of bone marrow, peripheral blood, and spleen
demonstrated the presence of different hematopoietic lineages in
individual litters (Figure 1D). The transplanted stem cells gave rise
to both human B cells (CD191) and T cells (both CD4 and CD8).
Foxp31 regulatory T cells were also detected in chimeric mice,
particularly in the bone marrow (Figure 1D). Additionally, we
established the presence of human CD341 cells in the bone
marrow of chimeric animals (Figure 1D). Compiled lineage data
from 10 individual mice with bone marrow CD341 cell engraftment
demonstrate the range of human lineage distribution in this model
(Figure 1E). We looked for the presence of human red blood cells in
our mice but did not detect any. This finding is consistent with other
reports in humanized mice, and the reason is thought to be
secondary to destruction of human red blood cells by host murine
macrophages and murine complement.25,26
Circulating levels of human cells were lower than those seen in the
lymphoid organs of chimeric animals (Figure 2A). The engraftment
results determined by flow cytometry were supported by histolog-
ical analysis. In the spleens, we detected T cells in organized
structures similar to lymphoid follicles and a smaller portion of
B cells in structures similar to germinal centers (Figure 2B). We
found higher percentage of T-cell engraftment than typically noted
in adult transplanted NSG mice, which may reflect homeostatic
proliferation of T cells, as our CD341 human samples were not
completely pure and did contain a percentage of human T cells
(3% to 17%). Earlier transplantation of human cells into NSG mice
results in higher percentage of T cells when compared with adult
transplantation,27 which may be taking place within our model.
Although chronic graft-versus-host disease (GVHD) has been
implicated in high T-cell numbers in NSG mice that receive human
CD341 cells,28 our mice showed no physical evidence of GVHD at
24 weeks. Our mice also had B cell percentages as high as 50% to
65%, which is further evidence of true engraftment rather than
chronic GVHD. Our experience with in utero injections have also
demonstrated that the fetal host is remarkably resistant to GVHD.29
Fetal host conditioning increases engraftment rate
Although the in utero transplantation model allows transplantation
of allogeneic or xenogeneic cells without host conditioning, the
levels of engraftment could be improved by using a nontoxic
strategy to increase space in the hematopoietic niche. One such
strategy is in utero treatment with ACK2, a monoclonal antibody that
depletes hematopoietic stem cells (HSCs) by blocking the function
of the murine c-Kit receptor.16 We have previously demonstrated
that this antibody can be used in the fetal transplantation setting to
improve engraftment of mouse fetal liver–derived HSCs.17 Because
murine ACK2 does not inhibit human HSC survival, we next
coinjected 2.5 mg/pup of ACK2 along with human cord blood–
derived CD341 cells at E14.5. Based on our previous work, human
HSCs are only inhibited at doses 103 this dose, and this is the
optimum dose for murine fetal HSC depletion.17 Survival of injected
pups was 33% (16/49) to birth and 24% (12/49) survival to wean,
with no significant difference in the survival outcomes compared with
injection of cells alone. Ten of the 12 surviving pups were chimeric
(83%), representing a significant increase in the rates of engraftment
compared with no ACK2 treatment (P, .05) (Figure 2C). The overall
levels of chimerism were not significantly different (Figure 2D).
We did not observe the significant human myeloid cell engraftment
seen in other models of NSG mice that use irradiation. We believe
this may be secondary to the less space created in the niche with
ACK2 relative to irradiation. Additionally, stem cell factor expression is
increased with irradiation. In a transgenic NSG model that expressed
membrane-bound human stem cell factor, human myeloid cell
engraftment is increased in both irradiated and nonirradiated
hosts.27,30 Our levels of granulomonocytic hematopoiesis are
comparable to those found in models of NSG mice in which there
is no irradiation for preconditioning.27 However, because ACK2
increases the rate of chimerism, this strategy can be used as an
adjunct to improve the efficiency of in utero transplantation.
Engraftment of human lymphocytes in critical
mucosal sites after in utero transplantation
Given the importance of hematopoietic reconstitution of mucosal
surfaces for the study of human disease, we assessed for human
cells in respiratory, reproductive, and gastrointestinal mucosa using
immunohistochemistry and flow cytometry. This analysis revealed a
relatively high frequency of human cells in all examined mucosal sites.
Local tissue environment appeared to guide HSC differentiation, as
we found different ratios of human leukocytes in different tissues. In
the lungs, the majority of human (CD451) hematopoietic cells were
hCD31, hCD41 and hCD81 T lymphocytes (Figure 2E), with fewer
macrophages. In the gastrointestinal tract, we observed human
CD451 cells in both the small and large intestine (Figure 2F). Donor-
derived CD451 human cells were also observed throughout the
tissues of the female reproductive tract (including the vagina, cervix,
and uterus) (Figures 1 and 2G). We did not observe any significant
GVHD in transplanted mice (supplemental Figure 2).
Engraftment of human lymphocytes in the brain after
in utero transplantation
The ability to transplant human cells prior to formation of the
blood–brain barrier, which occurs at;E15.5 in mice,31 may present
an opportunity to engraft human cells within the brain. We observed
Figure 2. Human CD45
1
cells show systemic multilineage engraftment with increased engraftment rates following ACK2 treatment. (A) Percentage of human
CD451 cells in lymphoid tissues of chimeric mice and peripheral blood. *P , .05, ***P , .001, ****P , .0001 (analysis of variance with Tukey’s honest significance test). (B)
Immunohistochemistry of harvested spleen from a T-cell–dominant mouse demonstrating organized lymphoid follicles. (original magnification 310; immunohistochemical
analysis was performed on fixed/paraffin-embedded tissue sections for human CD451, CD31, CD41, CD81, CD201, and CD681 then counterstained with hematoxylin)
(C) Effect of ACK2 treatment on the rates of engraftment (the proportion of surviving animals with $1% chimerism in any tissue). (D) Overall chimerism levels. (E-H) NSG mice
treated with in utero transplantation of human CD341 cells demonstrate populations of human cells, within the lung alveolar and bronchiole tissue (E), small and large bowel
(F), female reproductive tract (G), and brain (H) (original magnification 340; immunohistochemical analysis was performed on fixed/paraffin-embedded tissue sections for
human CD451, CD31, CD41, CD81, CD681, and CD201 and counterstained with hematoxylin). BM, bone marrow; LN, lymph nodes; PB, peripheral blood.
human hematopoietic cells (CD451) in the brainstem and cerebral
cortex of chimeric mice; serial sectioning revealed these cells to be
T cells (hCD31, hCD41, and hCD81) and hCD681 macrophages
(Figure 2H). The presence of human cells in the brain raises the
possibility of using in utero transplantation to deliver cells into the
brain for the treatment of neurological disorders.
In this study, we have demonstrated efficient systemic engraftment of
human hematopoietic stem cells in NSG mice after in utero trans-
plantation without the need for host irradiation. In future experiments, it
will be important to determine whether repeated transplantation of
human CD341 further boosts engraftment and to investigate the ability
of the stem cells in these mice to repopulate secondary recipients. This
model will be useful for analysis of human stem cell plasticity, in vivo
repopulation, and tissue-specific immunity during infection.
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